Will AbbVie Reconsider the $51B Shire Deal?

The video discusses the current market news, focusing on AbbVie's reconsideration of its takeover of Shire due to US Treasury's crackdown on inversion deals. The potential for a cheaper offer from AbbVie is explored, along with the market reactions, including the impact on Shire and AstraZeneca shares. The video also analyzes the business strategies involved and the implications of US Treasury rules.

Who are the individuals mentioned as joining the discussion on market news?

• David Brown and Emily White

• Matt Millen and Olivia Sterns

• John Doe and Jane Smith

• Michael Johnson and Sarah Lee

Why is AbbVie reconsidering its proposed takeover of Shire?

• AbbVie's internal financial issues

• Due to a change in Shire's management

• Shire's declining market value

• Because of US Treasury's crackdown on inversion deals

What is the impact on Shire's shares following the news?

• Shares decreased by 30%

• Shares decreased by 10%

• Shares increased by 10%

• Shares remained stable

What strategic move might AbbVie consider regarding the Shire deal?

• Increasing the offer price

• Selling its own shares

• Backing off to negotiate a lower price

• Merging with another company

What is the value of the break clause in the AbbVie-Shire deal?

• $2 billion

• $1.6 billion

• $500 million

• $50 million